Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil in Heart Failure With Reactive Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known chronic heart failure appropriately treated with Angiotensin converting enzyme (ACE) inhibitors and beta blockers, unless contraindicated or poorly tolerated~* indication for right heart catheterization~* pulmonary artery mean pressure \>25 mmHg~* pulmonary capillary wedge pressure \> 15 mmHg~* pulmonary vascular resistance \> 3 Wood units~Exclusion Criteria:~* hypersensitivity, allergy, or intolerable side effect to sildenafil~* history of primary pulmonary hypertension, connective tissue disorder, severe chronic obstructive pulmonary disorder (COPD), pulmonary embolism, or left to right shunt~* co-morbidities, limited exercise intolerance:~  * morbid obesity (BMI \>40)~ * COPD with oxygen dependence~ * severe peripheral vascular disease with intermittent claudication~ * status post amputation of lower extremity at any level~ * severe degenerative joint disease preventing normal walking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo three times per day, orally
- Sildenafil (Type: ACTIVE_COMPARATOR): Sildenafil 20 mg three times per day, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).